Latest developments in metal complexes as anticancer agents

Potent Chlorambucil-Platinum(IV) Prodrugs

“…Four other platinum-based drugs are also available for chemotherapeutic use, but their regulatory approval is exclusive to selected countries: nedaplatin and miriplatin (Japan), lobaplatin (China), and heptaplatin (South Korea), respectively ( Figure 1 ) [ 4 ]. In addition to platinum, many other metal coordination complexes have been discovered and gained therapeutic interest because of their distinctive architectures and the unique properties that result [ 4 , 5 ]. This productive area of research is inspired by the desire to discover cancer’s magic bullet.…”

Tunable Emissive Ir(III) Benzimidazole‐quinoline Hybrids as Promising Theranostic Lead Compounds

“…Both complexes have C 1 molecular symmetry as well as a helicoidal chirality implicit in the trichelated octahedral complexes. Their asymmetric nature due to presence of a L1 and L2, leaded to the non-equivalence of the two phenylpyridines (ppy) in each complex, rendering two set of different signals in 1 H and 13 C-NMR for the ppy. Consequently, the singlet observed for the protons of CH 2 group in the ligands L1 and L2 Figure 1.…”

“…The necessity of finding additional metallodrugs to cisplatin is boosting research into new, and very promising, metal‐based structures such as those derived from Ru(II), Au(I/III), very recently Ir(III) [1] or combination of those [2–4] . The key point is to deliver drugs able to reveal their therapeutic potential by a mechanism of action different from that of cisplatin, in order to avoid the so‐called ‘platinum resistance’ [5] and its adverse side effects [6] .…”

A multiscale free energy method reveals an unprecedented photoactivation of a bimetallic Os(ii)–Pt(ii) dual anticancer agent

“…6,7 In recent years, remarkable advances have been made toward the design of next-generation PS (sometimes referred as fourthgeneration) able to display a multiple reactivity against cancer and conceived with the aim to tackle the current limitations of PDT in the clinic. 8 In this field, Ru(II)-polypyridil complexes [9][10][11][12] are receiving a growing attention especially since the McFarland's first Ru(II)-complex TLD-1433 has entered phase II clinical trials for the treatment of non-muscle invasive bladder cancer. [13][14] That compound also displays a promising TypeI/TypeII dual photoreactivity exerting its phototoxicity at a. Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Arcavacata di Rende 87036, Italy b. Departament de Química Física, Universitat de València, Burjassot 46100, Spain Electronic Supplementary Information (ESI) available: [NTOs for the singlet states, HOMO and LUMO orbitals, M06 and ZORA-M06 excitation energies, benchmark for the Pt-Cl bond breaking, QM/MM Mulliken spin densities, a sensitivity analysis of the PMF integration limits, histogram of the Pt-O distances collected in the umbrella sampling technique, and umbrella sampling windows and complete simulation times.].…”